Evidence map›Paper›PMID 34032767›Full record

ArticleMedicine2021

Long-term response on letrozole for gastric cancer: A case report.

Yuuki Iida, Kumiko Hongo, Takanobu Onoda, Yusuke Kita, Yukio Ishihara, Naoki Takabayashi, Ryo Kobayashi, Ken Kuriki, Takeyuki Hiramatsu

Open access · goldAbstract readCase Reports
In one paragraph

Article in Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yuuki IidaDepartment of Surgery, Yaizu City Hospital.ORCID 0000-0003-2929-9619
Kumiko HongoDepartment of Surgery, Yaizu City Hospital.
Takanobu OnodaDepartment of Surgery, Yaizu City Hospital.
Yusuke KitaDepartment of Surgery, Yaizu City Hospital.
Yukio IshiharaDepartment of Surgery, Yaizu City Hospital.
Naoki TakabayashiDepartment of Surgery, Yaizu City Hospital.
Ryo KobayashiDepartment of Surgery, Yaizu City Hospital.
Ken KurikiDepartment of Pathology, Yaizu City Hospital 1000 Dobara, Yaizu city, Shizuoka, Japan.
Takeyuki HiramatsuDepartment of Surgery, Yaizu City Hospital.
Shizuoka University of Welfare · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleHormone therapies, particularly those targeting estrogen and its receptors, are a key treatment modality for patients with estrogen receptor (ER)-positive breast or ovarian cancer. Some gastric cancers (GCs) express ERs, and preclinical studies suggest the potential of estrogen-targeting hormone therapy on GC; however, the clinical relevance of this hormone therapy on GC treatment has not been well elucidated. PATIENT CONCERNS: An 80-year-old female was admitted to our department with hypogastric pain and vomiting. Computed tomography demonstrated small bowel obstruction, and laparotomy after bowel decompression revealed peritoneal dissemination consisting of a poorly-differentiated adenocarcinoma. Intestinal bypass between the ileum and transverse colon was performed. DIAGNOSES: The tumor was ER- and mammaglobin-positive, indicating that it originated from a breast cancer. Diagnostic imaging revealed no evidence of breast cancer; however, right axillary ER- and mammaglobin-positive lymphadenopathy was found.

interventionsThe patient received hormone therapy using letrozole based on a clinical diagnosis of occult breast cancer with peritoneal dissemination and right axillary lymph node metastasis. OUTCOMES: The patient remained disease free until 37 months but deceased at 53 months from the onset of disease. An autopsy revealed no tumor cells in the right breast tissue; however, there was a massive invasion of cancer cells in the stomach. LESSONS: A patient with ER positive GC with peritoneal dissemination and right axillary lymph node metastasis presented remarkable response to letrozole. The long-term survival obtained using letrozole for a patient with GC with distant metastasis suggests the potential of estrogen targeting hormone therapies for GC.

Indexed as

AdenocarcinomaAged, 80 and overAntineoplastic AgentsBreast NeoplasmsFatal OutcomeFemaleHumansLetrozoleLymphatic MetastasisReceptors, EstrogenStomach NeoplasmsAntineoplastic AgentsLetrozoleReceptors, Estrogen

Identifiers

PMID34032767
PMCPMC8154479
OpenAlexW3164906971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.